NCT03378466 (HALO) is a Phase 2 clinical trial of Unfractionated heparin in Septic Shock, sponsored by University of Manitoba.

Who is sponsoring NCT03378466?

NCT03378466 is sponsored by University of Manitoba.

What drugs are being tested in NCT03378466?

Interventions in NCT03378466: Unfractionated heparin, Venous thromboprophylaxis (VTE).

What condition does NCT03378466 study?

NCT03378466 studies Septic Shock, Vasodilatory Shock.

Is NCT03378466 still recruiting?

NCT03378466 is currently terminated. Last updated 24 May 2022.

Last reviewed 2022-05-24 · How we verify

NCT03378466: HALO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heparin Anticoagulation in Septic Shock

Terminated Phase 2 Last updated 24 May 2022

What this trial tests

Phase 2 trial testing Unfractionated heparin in Septic Shock in 178 participants. Terminated before completion.

Timeline

12 March 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	University of Manitoba
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	178
Start date	12 March 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	51 locations across Pakistan, Greece, Philippines, Canada, United States, Brazil, India

Drugs / interventions tested

Unfractionated heparin — full drug profile →
Venous thromboprophylaxis (VTE)

Conditions studied

Septic Shock — all drugs for Septic Shock →
Vasodilatory Shock — all drugs for Vasodilatory Shock →

Sponsor

University of Manitoba

Who can join

18 and older, any sex, with Septic Shock or Vasodilatory Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a pragmatic open-label international randomized trial comparing therapeutic dose intravenous unfractionated heparin (UFH) to standard care venous thromboprophylaxis in patients diagnosed with septic shock.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
Tarighi P, Eftekhari S, Chizari M, Sabernavaei M, et al · · 2021 · cited 80× · PMID 33482181 · DOI 10.1016/j.ejphar.2021.173890
Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.
Godoy LC, Goligher EC, Lawler PR, Slutsky AS, et al · · 2020 · cited 34× · PMID 32816822 · DOI 10.1503/cmaj.201240
Computational approaches for drug repositioning and repurposing to combat SARS-CoV-2 infection
Panda S, Kumari L, Badwaik H, Shanmugarajan D. · · 2022
Prévoir et gérer la coagulopathie et les manifestations thrombotiques de la COVID-19 sévère.
Godoy LC, Goligher EC, Lawler PR, Slutsky AS, et al · · 2020 · PMID 33318097 · DOI 10.1503/cmaj.201240-f

Verify or expand the search:

Other trials of Unfractionated heparin

Trials testing the same drug.

NCT07361783 — Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial · NA · recruiting
NCT06442267 — Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support · Phase 4 · recruiting
NCT05959252 — BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation · Phase 2 · recruiting
NCT06174961 — The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin · Phase 4 · completed
NCT05255848 — Nebulised Heparin in Patients With COVID-19 Pneumonia · Phase 2, PHASE3 · unknown

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other University of Manitoba trials

Trials by the same sponsor.

NCT07528417 — Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) · Phase 2 · not yet recruiting
NCT07366515 — Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients · NA · not yet recruiting
NCT07354386 — Effects of Dried Whole Fruits on Metabolism in Diabetes · NA · enrolling by invitation
NCT07361315 — Development and Online Evaluation of an Online Course for Parasomnias · NA · recruiting
NCT07023744 — CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03378466 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Manitoba
Last refreshed: 24 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03378466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing